We call upon the Government of Canada to clarify whether or not type 1 diabetes qualifies for the Disability Tax Credit program, and for the government to remove all unnecessary barriers to insulin and supply access for people with diabetes. We support calls for the creation of a national universal pharmacare program, a frequently stated priority of the Canadian government, and note such a program would render this entire debate moot. Read more
I joined dozens of people impacted by the rising cost of insulin in the USA in protest of those prices in front of Eli Lilly headquarters in Indianapolis, Indiana. Some had traveled many hours to join the protest, but one thing was made clear, we wanted to ensure that Eli Lilly heard our voices. We were passionate in our outcry for change and jointly understood that not saying anything is simply not an option.
Patients and those who support us will be demonstrating outside of Eli Lilly HQ in Indianapolis on Saturday, September 9th 2017. See the full post for more information and join us at https://www.facebook.com/groups/insulin4allAction/ if you can be there.
In the wake of rising insulin prices in the United States and recent threats to public health safety nets like Medicaid, patients with type 1 diabetes are becoming increasingly more vulnerable. As a member of the T1D community and a rising second year Masters student at the Yale School of Public Health, Samantha Willner is hoping to shed light on the terrible sacrifices members of the T1D community in the U.S. have had to make in order to get the medicine they need to live. Read more
Sixteen organisations have signed an open letter to Dr. Tedros Adhanom Ghebreyesus, the incoming Director-General of the World Health Organization. The letter, penned by T1International, praises his attention to diabetes and requests that more focus is put on access to insulin and treatment for everyone living with diabetes around the world. Read more
Recently, I was lucky enough to attend Camp Waromo, a four-day diabetes camp hosted by the Sonia Nabeta Foundation (SNF), a wonderful organisation working to ensure that everyone with diabetes in Africa has access to medicine and support they need. T1International was honoured to be invited and to share our advocacy resources and knowledge. Read more
Many of you supported T1International’s Insulin for Syrians campaign last year, when we raised funds for our partner organisation, the Syrian American Medical Society (SAMS) to ensure that people living with diabetes amidst the crisis in Syria would be able to have access to insulin and basic supplies. Read this update about the situation now and how your donation helped. Read more
The law firm Hagens Berman has filed a complaint against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices. Read more
What did T1International achieve in 2016? Lots! We raised funds to get insulin to Syrians in need, we carried out our Insulin & Supply survey to show how unaffordable type 1 diabetes really is, we launched the Type 1 Access Charter as well as the Advocacy toolkit, and so much more! Read more
Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more